12.72
-0.16 (-1.24%)
| Previous Close | 12.88 |
| Open | 12.92 |
| Volume | 774,187 |
| Avg. Volume (3M) | 2,123,450 |
| Market Cap | 726,119,168 |
| Price / Sales | 1.03 |
| Price / Book | 5.21 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 17.39 |
| Operating Cash Flow (TTM) | -96.14 M |
| Levered Free Cash Flow (TTM) | -62.11 M |
| Return on Assets (TTM) | -22.56% |
| Return on Equity (TTM) | -32.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Astria Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.75 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.49% |
| % Held by Institutions | 106.43% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |